The Expression of TLR-9, CD86, and CD95 Phenotypes in Circulating B Cells of Patients with Chronic Viral Hepatitis B or C before and after Antiviral Therapy

Table 3

Treatment with adefovir dipivoxil modulates clinical profiles of HBV patients.

Parameters	0 weeks	12 weeks	24 weeks
HBV DNA (log10 copies/mL)
Median (range)	8,4 (5,7–9,8)	3,5 (1,9–5,8)^*	2,5 (1,8–4,1)^*
ALT (U/L)
Median (range)	219 (12–914)	45 (16–171)^*	24 (10–148)^*
AST (U/L)
Median (range)	117 (22–221)	27 (18–123)^*	22 (16–54)^*
HBsAg (IU/mL)
Median (range)	4697,68 (1243,65–55925,04)	3478,45 (890,34–17118,09)	1729,56 (356,71–12315,86)^*
HBsAb (mIU/mL)
Median (range)	0,06 (0–3,71)	0,4 (0–4,41)	3,56 (0,52–8,56)^*
HBeAg (S/CO)
Median (range)	3233,3 (3,88–4094,10)	539,62 (0,47–2345,67)^*	21,3535 (0,35–766,13)^*
HBeAb (S/CO)
Median (range)	16,74 (0,02–46,74)	1,26 (0,01–35,67)^*	0,46 (0–16,23)^*

Normal values: ALT ≤ 40 IU/L; AST ≤ 40 IU/L; HBV DNA ≤ 3 log₁₀ copies/mL.
< 0.05 patients after treatment with adefovir dipivoxil versus patients at baseline.